Celyad Oncology SA · EURONEXT:CYAD
Celyad Oncology SA — Celyad — Investor Presentation (July 2017)
33 slides from Celyad Oncology SA's investor presentation, July 2017
Slide 1: Corporate Presentation July 2017
Bringing Breakthrough Pioneering Therapies to Patients with Life-Threatening Diseases Corporate Presentation July 2017
Slide 2: Disclaimer
Disclaimer In addition to historical facts or statements of current condition, this presentation contains forward-looking statements, including statements about the potential safety and feasibility of CAR-T cell therapies, which reflect our current expectations and projections about future events, a
Slide 3: Celyad: Company overview
Celyad: Company overview Focused on the discovery and the development of specialized cell-based therapies to target cancer • Novel and proprietary CAR-T platform targeting treatment of solid and hematological tumors. • Lead candidate, CYAD-01 (CAR-T NKG2D), currently enrolling in Phase I THINK trial
Slide 4: Celyad's immuno-oncology pipeline is promising
Celyad’s immuno-oncology pipeline is promising 2015 2016 2017 2018 CLINICAL STAGE Autologous platform CYAD-01 (CAR-T NKG2D) SAFETY THINK - Acute Myeloid Leukemia HEMATO CANCER Phase 1 Trial THINK - Multiple Myeloma INDICATIONS THINK - Ovarian cancer THINK - Colorectal cancer THINK - Pancreatic cance
Slide 5: CYAD-01: A unique construct arming T-cells with an NK receptor
CYAD-01: A unique construct arming T-cells with an NK receptor to target and destroy cancer cells • One natural construct that capitalizes on the two main pillars of the immune system: NK cells and T-cells. • A natural co-stimulating domain: DAP 10 • Same signaling domain as other CAR-T: CD3ζ 5
Slide 6: A single NK cell receptor binding 8 different ligands
A single NK cell receptor binding 8 different ligands NKG2D can bind to any of eight naturally occurring ligands known to be overexpressed in more than 80% of solid and hematological tumors NKG2D Binding Ligands MICA MICB ULBPs 1-6 NKG2D ligands are expressed by stressed cells during infection, tumo
Slide 7: NKG2D expresses ligands in broad range of cancer indications
NKG2D expresses ligands in broad range of cancer indications Expression of at least one of NKG2D ligands: • Triple negative breast cancers : 88% • Colorectal cancers : 88% • Ovarian cancers: 68% • Bladder cancers: 78% of the primary tumors and 100% of the metastases • Pancreatic cancers: 86% • NSCLC
Slide 8: CYAD-01: A novel paradigm to CAR-T
CYAD-01 : A novel paradigm to CAR-T The next frontier of cell therapy Increasing deliverability and safety Less controlled In Vivo Controlled dosing and PK Next Generation CYAD-01 Expansion with potential to reduce adverse events A cell transplant paradigm for serious adverse events and increase Eff
Slide 9: CYAD-01 Modes of action identified from pre-clinical mouse models
CYAD-01 Modes of action identified from pre-clinical mouse models • Eradication of established tumors by multiple infusions of CYAD-01 with no pre-conditioning chemotherapy • Short term persistence (7-10 days) • Direct target cell killing • Modulation of the local tumor microenvironment • Reduced nu
Slide 10: CYAD-01 Mediate cytotoxicity and cytokine release during challenge with tumor cells
CYAD-01 Mediate cytotoxicity and cytokine release during challenge with tumor cells Demoulin et al. Future Oncology 2017 10
Slide 11: CYAD-01 Cell activity in vivo against established Panc-1 tumor cells
CYAD-01 Cell activity in vivo activity against established Panc-1 tumor cells Demoulin et al. Future Oncology 2017 11
Slide 12: In vitro potency of CYAD-01
In vitro potency of CYAD-01 Cytotoxicity 120 T a r g e t c e ll k illin g ( % ) 100 80 60 40 20 0 Cytotoxicity mediated by CYAD-001 CAR T cells produced under GMP compliant conditions Kinetics of killing of pancreatic tumor cells by CYAD-001 CAR T cells 12
Slide 13: CYAD-01 autologous clinical program includes various studies
CYAD-01 autologous clinical program includes various studies 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study CM-CS-1 Study Single IV administration of CYAD-01 AML and MM relapsing post standard of care Open-label dose escalation Phase I study THINK Study Multiple IV administrations
Slide 14: CYAD-01: Clinical development plan
CYAD-01: Clinical development plan THINK: A multinational (EU/US), open-label, dose escalation Phase 1 study to assess the safety and clinical activity of multiple administrations of CAR-T NKG2D CAR-T NKG2D CAR-T NKG2D Phase 1 safety trial THINK Phase 1 trial • 1 administration • 3 administrations •
Slide 15: CYAD-01: Phase I safety trial successfully completed
CYAD-01: Phase I safety trial successfully completed 2015 2016 • Single administration, dose-escalation Phase I autologous CAR-T NKG2D study in patients with Acute Myeloid Leukemia and Multiple Myeloma CAR-T NKG2D Phase I Safety trial Dana Farber, last patient included in September 2016. ▪ 1 adminis
Slide 16: CYAD-01: THINK trial study design targeting seven refractory cancers
CYAD-01: THINK trial study design targeting seven refractory cancers Phase I dose escalation segment Phase I dose expansion segment 3 3 3 Bladder Solid tumors TN Breast 3x108 1x109 3x109 Colorectal All solid tumor types Ovarian Recommended dose Pancreatic 3 3 3 Hematological 3x108 1x109 3x109 tumors
Slide 17: CYAD-01: THINK trial (solid arm) promising early results
CYAD-01: THINK trial (solid arm) promising early results at first dose level Promising early results at first dose level (3x108) • Two metastatic colorectal cancer patients reported as Stable Disease at 3-month follow-up* • Refractory pancreatic patient was in progression at the same time point • No
Slide 18: CYAD-01 autologous clinical program includes various studies
CYAD-01 autologous clinical program includes various studies 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study CM-CS-1 Study Single IV administration of CYAD-01 AML and MM relapsing post standard of care Open-label dose escalation Phase I study THINK Study Multiple IV administrations
Slide 19: SHRINK study rationale
SHRINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SHRINK Study Multiple IV administrations of CYAD-01, combined with FOLFOX Potentially resectable liver metastases from colorectal cancer 1. To control the disease progression • During the manufacturing period, i
Slide 20: SHRINK study rationale
SHRINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SHRINK Study Multiple IV administrations of NKR-2, combined with FOLFOX Potentially resectable liver metastases from colorectal cancer 5. Strategic integration in standard anti-cancer treatment 6. Strategic inte
Slide 21: LINK study rationale
LINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study LINK Study Multiple hepatic transarterial administrations Unresectable liver metastases from colorectal cancer 1. The hepatic transarterial administration may offer the advantage of lower systemic toxicity and hig
Slide 22: SIBLINK study rationale
SIBLINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SIBLINK Study Multiple IV administration of SIBLING CYAD-01 AML relapsing post allo-HCT 1. Evaluate the “standard” CAR-T paradigm lymphodepletion Target Product Profile concept 2. Increase of the in vivo NKR-2
Slide 23: SIBLINK study rationale
SIBLINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SIBLINK Study Multiple IV administration of SIBLING CYAD-01 AML relapsing post allo-HCT 4. Strategic integration in standard anti-cancer treatment (“enriched” Donor Lymphocyte Infusion) 5. Strategic intention t
Slide 24: 2017 and 2018 clinical milestones
2017 and 2018 clinical milestones Q1 2017 Q2 2017 Q3 2017 Q4 2017 H1 2018 H2 2018 SOLID • Enrollment • Reporting • Reporting • Completion • Reporting • PFS 6- Dose 1 Dose 1 Dose 2 enrollment Dose 3 Month Data Completed Dose 3 • Completion • Enrollment enrollment • Start Expansion Dose 2 Expansion Se
Slide 25: 2017 and 2018 clinical milestones
2017 and 2018 clinical milestones Q1 2017 Q2 2017 Q3 2017 Q4 2017 H1 2018 H2 2018 Initiate Study Topline Data PFS 6-Month SHRINK Data Initiate Study Topline Data PFS 6-Month LINK Data Initiate Study Topline Data SIBLINK 25
Slide 26: Intellectual Property – Overview
Intellectual Property – Overview Three patent families covering autologous products pipeline • CYAD-01 (CAR-T NKG2D): two granted US patents, covering chimeric NK cell receptor CAR-Ts • CAR-T B7H6: pending applications in US, Europe, China and Japan on B7-H6 CAR-Ts B7-H6 is a ligand of the NKp30 rec
Slide 27: Intellectual Property – Allogeneic platform
Intellectual Property – Allogeneic platform One patent family covering allogeneic platform: • Three granted US patents, covering TCR-deficient T cells, methods of producing them, and methods to use them to treat cancer • >10 applications pending in different jurisdictions • Allogeneic patent provide
Slide 28: Financial snapshot
Financial snapshot Cash Position: • €72 million as of March 31, 2017 • Enabling company’s activities until Q2 2019 Ticker: Nasdaq (CYAD), Euronext Paris & Euronext Brussels (CYAD.BB) 28
Slide 29: Academic partnerships
Academic partnerships • Institut Curie is a world class research institution focusing on cancer and immunity, and positioning translational science at the heart of its approach • March 2016: Celyad entered into a 3 year collaboration with Institut Curie • CAR-T platform developed by Celyad was inven
Slide 30: Corporate partnerships
Corporate partnerships • Novartis is a global healthcare company based in Switzerland that provides solutions to address • ONO is a leader in cancer-immunotherapy in Japan the evolving needs of patients worldwide with the first approved checkpoint inhibitors, OPVIDO© • May 2nd, 2017: Celyad grants t
Slide 31: Management team
Management team 1. Christian Homsy, CEO 2. Patrick Jeanmart, CFO 3. Jean-Pierre Latere, COO 4. Frédéric Lehmann, VP Clinical Development & Medical Affairs 5. David Gilham, VP R&D 6. Georges Rawadi, VP Business Development & IP 1 2 3 7. Philippe Dechamps, Chief Legal Officer 8. Philippe Nobels, Globa
Slide 32: Celyad ADR programme
Celyad ADR programme Celyad ADRs trade on NASDAQ Benefits of ADRs to US investors • Symbol CYAD • Clear and settle according to US standards. • Cusip 151205000 • Offer the convenience of stock quotes and dividend payments in US dollars. • Ratio 1 ORD:1 ADR • Can be purchased/sold in the same way as
Slide 33: Thank you
Thank you Contact: investors@celyad.com BELGIUM USA Celyad SA Celyad Inc. Axis Business Park Seaport East Rue Edouard Belin, 2 2 Seaport Lane B-1435 Mont-Saint-Guibert Boston, MA. 02210 +32(0) 10 39 41 00 +1 857-990-6900 www.celyad.com